<DOC>
	<DOCNO>NCT02198443</DOCNO>
	<brief_summary>The main objective study compare tolerability adherence new drug regimen post-exposure prophylaxis ( PEP ) HIV ,</brief_summary>
	<brief_title>Comparison Two Combinations Antiretroviral Post-Exposure Prophylaxis HIV-1 : Tenofovir/Emtricitabine ( Truvada ® ) + Lopinavir/Ritonavir ( Kaletra ® ) v Tenofovir/Emtricitabine/Cobicistat/Elvitegravir ( Stribild ® ) . Prospective , Randomized , Open .</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Age great 18 year Have expose HIV , nonoccupational meet requirement current recommendation start three antiretroviral drug PEP adequately inform consent write participate study undergo test exploration entail pregnant woman , lactate , intend become pregnant study period . subject know suspected case present source resistor one drug pattern study contraindicate treatment study drug , product investigation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>